聚乙二醇化重组人粒细胞刺激因子预防卵巢癌化疗粒细胞减少症的临床治疗被引量：2

Role of pegylated recombinant human granulocyte stimulating factor in preventing chemotherapy-induced granulocytopenia in ovarian cancer

暂未订购

导出

摘要卵巢癌是妇科常见的恶性肿瘤。其恶性程度高,预后差,化疗是必要的辅助治疗手段。然而,化疗后最易并发粒细胞减少症,从而增加感染的风险,而且严重患者不能接受足量、足疗程化疗,从而降低化疗效果,甚至产生耐药等,直接影响预后。既往的研究发现,聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)是rhG-CSF经聚乙二醇化修饰后的长效剂型,每个化疗周期仅单次用药即可有效预防粒细胞减少症的发生,提高依从性[1]。本研究以上皮性卵巢癌为研究对象,采用随机平行对照的方法,比较单次给予PEG-rhG-CSF和连续给予rhG-CSF预防化疗导致的粒细胞减少症的临床疗效和安全性。

作者王丽梅孟春玉孙胜男刘晓艳王树鹤

机构地区解放军总医院第七医学中心妇产科河北燕郊人民医院妇产科

出处《武警医学》 CAS 2020年第7期609-611,共3页 Medical Journal of the Chinese People's Armed Police Force

关键词聚乙二醇化重组人粒细胞刺激因子卵巢癌粒细胞减少症

分类号 R733.71 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1石远凯,许建萍,吴昌平,张燕,杨俊泉,周涛,刘峥,茅卫东,张沂平,王嵬,于忠和,邬麟,陈建华,王娟,安永辉,蔡建辉,刘明,陈振东,李青山,任朝英,杨志勇,李宝兰,赵敏,刘哲峰,刘斌.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少症的多中心上市后临床研究[J].中国肿瘤临床,2017,44(14):679-684. 被引量：45
2徐兵河,田富国,喻璟瑞,宋艳秋,石建华,张百红,张燕军,袁志平,吴穷,张清媛,南克俊,孙强,李维廉,胡建兵,毕经旺,孟春,戴红,蒋宏传,岳顺,曹邦伟,孙玉萍,王殊,佟仲生,沈朋,伍钢,唐利立,邓甬川,贾立群,沈坤炜,庄武,谢晓冬,伍尤华,陈琳.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对照Ⅲ期临床研究[J].中华肿瘤杂志,2016,38(1):23-27. 被引量：43

二级参考文献11

1石远凯,周际昌,冯奉仪,曾万勇,李青,何小慧,张弘刚,张湘茹,周立强.基因重组人粒细胞集落刺激因子对肿瘤化疗所致白细胞减少的临床疗效观察[J].中华肿瘤杂志,1994,16(3):207-210. 被引量：35
2石远凯,刘鹏,杨晟,韩晓红,何小慧,艾斌,秦燕,李博,黄鼎智,张长弓,孙燕.注射用聚乙二醇化重组人粒细胞集落刺激因子I期临床耐受性试验[J].癌症,2006,25(4):495-500. 被引量：32
3杨晟,石远凯,刘鹏,韩晓红,何小慧,蔡永明,陈拯民.注射用聚乙二醇化重组人粒细胞集落刺激因子Ⅰ期临床药效学[J].中国医学科学院学报,2006,28(3):339-344. 被引量：13
4石远凯,何小慧,杨晟,王华庆,江泽飞,朱允中,克晓燕,张阳,刘云鹏,张伟京,王昭,石庆芝,谢晓冬,张贺龙,王杰军,罗德云,郑青山,孙瑞元.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少症的多中心随机对照Ⅱ期临床研究[J].中华医学杂志,2006,86(48):3414-3419. 被引量：43
5Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy[J]. Cancer Treat lRev, 2002, 28 (Suppl A): 13-16.
6Klastersky J, Awada A. Prevention of febrile neutropenia in chemotherapy- treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice? [J]. Crit Rev Oncol Hematol, 2011, 78(1):17-23. DOI: 10.1016/j.critrevonc.2010. 02.005.
7Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia : a muhicenter dose-finding study in women with breast cancer [ J ]. Ann Oncol, 2002, 13 (6) : 903-909. DOI: 10. 1093/annonc/ mdfl30.
8Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage 1~/N breast cancer[J]. J Clin Oncol, 2002, 20(3):727-731. DOI: 10.1200/JCO. 20.3. 727.
9Green MD, Koelbl H, Baselga J, et al. A randomized double- blind multicenter phase HI study of fixed-dose single- administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy [ J ]. Ann Oncol, 2003, 14(1) :29-35. DOI: 10.1093/annonc/mdgO19.
10Yang BB, Kido A. Pharmacokinefics and pharmacodynamics of pegfilgrastim [ J ]. Clin Pharmacokinetic, 2011, 50 ( 5 ) : 295-306. DOI~ 10.2165/115.